Compare DLNG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | MDWD |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Greece | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 162.2M |
| IPO Year | 2013 | 2013 |
| Metric | DLNG | MDWD |
|---|---|---|
| Price | $3.18 | $13.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 61.2K | ★ 95.0K |
| Earning Date | 11-19-2026 | 11-12-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $39.60 |
| Revenue Next Year | $1.10 | $34.34 |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.25 | $11.80 |
| 52 Week High | $4.45 | $19.70 |
| Indicator | DLNG | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 27.02 | 55.55 |
| Support Level | N/A | $12.76 |
| Resistance Level | $3.96 | $14.06 |
| Average True Range (ATR) | 0.09 | 0.56 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 11.96 | 70.32 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.